AimsDiabetes mellitus is a global health challenge requiring innovative solutions for early diagnosis, personalized treatment, and ongoing management. This review aims to examine the impact of artificial intelligence (AI) on diabetes care, focusing on precision diagnosis, tailored therapies, and real-time monitoring, while addressing challenges related to model transparency and equitable access to healthcare.MethodsWe conducted a comprehensive review of AI applications in diabetes management. Studies utilizing supervised and unsupervised learning, deep learning, federated learning, and reinforcement learning were analyzed for predictive accuracy, clinical impact, and integration. Comparisons with conventional methods were also included.ResultsMachine learning models show strong predictive performance for diabetes risk assessment, with random forest algorithms reporting accuracy up to 97% in hospital-based datasets. Deep learning models applied to clinical cohorts have achieved approximately 94.6% accuracy in predicting adverse events in patients with type 2 diabetes. Reinforcement learning approaches for automated insulin delivery have maintained glucose within the normoglycemic range for up to 95.66% of simulated time in artificial pancreas studies. Federated learning enables privacy-preserving collaborative model development with performance comparable to centralized models. AI-driven decision-support systems and wearable technologies further support improved glycemic monitoring and patient self-management. However, model performance varies depending on dataset characteristics, patient populations, and evaluation protocols.ConclusionsAI has reshaped diabetes care by enabling precise diagnosis, individualized treatments, and adaptive disease management. Responsible implementation is essential to address ethical concerns and ensure equitable access. Future work should refine AI frameworks for broader clinical adoption, prioritizing patient-centered care and data security.
Aburjaı et al. (Wed,) studied this question.